The Democratic Republic of Congo (DRC), the largest country in sub-Saharan Africa, ranks among the five poorest nations worldwide. Approximately one in six individuals live in extreme poverty, a condition largely stemming from the DRC’s long history of conflict, political upheaval and authoritarian rule. This tumultuous history has left the economy in turmoil and unpredictability. The lack of political and social stability makes managing international aid and establishing a proper health care system difficult, resulting in an extremely high disease burden.

Neglected Tropical Diseases

Neglected tropical diseases (NTDs) are bacterial and parasitic diseases that thrive in tropical environments, currently affecting more than one billion individuals worldwide, especially those in low-income countries and marginalized populations. Despite their devastating impact on health, the pharmaceutical industry pays relatively little attention to NTDs due to financial disincentives to research and develop new treatments for impoverished populations. Individuals affected by NTDs often face stigma within their communities, which further hinders their access to necessary care.

DNDi’s Focus On Sleeping Sickness

The Drugs for Neglected Diseases Initiative (DNDi) is a nonprofit research and development organization focusing on the lack of awareness surrounding NTDs and is actively working to develop new treatments for sleeping sickness. Currently, about 65 million individuals in the rural areas of sub-Saharan Africa are at risk of contracting sleeping sickness. Specifically, in the last five years, the DRC has reported 61% of all cases, highlighting a staggering need for concern and action.

Sleeping sickness, transmitted through tsetse fly bites, initially causes symptoms like fever, chills and headaches in infected individuals. These symptoms quickly progress to attack the central nervous system, leading to sleep disruptions, severe neuropsychiatric disorders, convulsions and potentially a coma. Without treatment, sleeping sickness usually proves fatal rapidly.

Complicating its treatment, the initial symptoms of sleeping sickness closely resemble those of malaria, another prevalent disease in the DRC. This similarity often leads to misdiagnosis and mistreatment, with the correct diagnosis frequently coming too late. Historically, the only available treatment was melarsoprol, an arsenic derivative that carried a fatality rate of 10-50%. Additionally, factors like massive population displacement, violence and persistent poverty in the DRC exacerbate this and other epidemics, hindering effective treatment efforts.

Recognizing these ongoing challenges, the DNDi acknowledges the critical importance of early diagnosis to prevent the progression of symptoms to the neurological stage. DNDi is urgently investing in the research and development of safe and effective treatments for sleeping sickness.

DNDi Receives Impactful Grant

The DNDi received a $12 million grant from the Bill and Melinda Gates Foundation to accelerate the development of an innovative new drug for sleeping sickness. DNDi has already revolutionized treatment with Fexinidazole, a new single-pill, single-dose medication. Along with a new rapid diagnostic test, this grant has significantly advanced the sustainable elimination of the disease. The funding will continue until the end of 2027 to support the delivery of this new cure to various rural areas in the DRC. The World Health Organization (WHO) and DNDi are optimistic about reaching and sustaining zero cases of sleeping sickness in the DRC by 2030.

Optimistic Future Ahead

Health professionals have screened more than 2 million individuals for sleeping sickness, including 749 patients from the DRC, where the new innovative drug, Fexinidazole, has proven effective and safe for adults and children. This advancement and continued treatment efforts offer hope for the DRC’s future in combating disease burden and poverty.

– Kewe Chen

Kewe is based in Memphis, TN, USA and focuses on Good News and Global Health for The Borgen Project.

Photo: Flickr